Bioenvision has closed its acquisition of Pathagon, a privately held company focused on the development of novel anti-infective products and technologies. With the acquisition, Bioenvision adds to its portfolio the rights to two FDA approved and marketed anti-infective technologies, OLIGON (TM) and methylene blue. Dr. Chris Wood MD, Bioenvision’s President & CEO, commented, “we are Read more about Bioenvision Completes Acquisition Of Pathagon[…]